Mymetics Corp (MYMX) 0.0234 $MYMX Malaria - Pipeline

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2015 at 1:23 AM

Mymetics Corp (MYMX) 0.0234 $MYMX

Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.99 (-0.01), PFNX: 18.98 (+2.17), INO: 9.78 (-0.18), CMRX: 37.54 (+0.36), RPTP: 10.58 (-0.10), IBIO: 0.90 (-0.15), ANAC: 61.41 (+1.07), PFE: 35.44 (+0.41), GNCA: 13.05 (-0.20), GSK: 48.23 (+0.51), AZN: 69.91 (-0.25), NVS: 103.58 (+1.01)

Mymetics Announces New Collaboration to Advance the Development of an Innovative Malaria Vaccine Candidate
Marketwired - Wed Nov 19, 3:27PM CST
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. MVI is a global program whose objective is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.

Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 24.65 (+0.16), CMRX: 37.54 (+0.36), CVM: 0.99 (-0.01), ADMP: 4.54 (+0.63), GNCA: 13.05 (-0.20)

Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute
Thomson Reuters ONE - Mon Sep 29, 6:03PM CDT
Mymetics Corporation and Texas Biomedical Research Institute / Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Mymetics Signs Agreement to Manufacture Virosome based HER-Vaxx Cancer Immunotherapy
Marketwire - Tue Jul 15, 7:00PM CDT
Mymetics (OTCBB: MYMX) announced today that it has signed an exclusive agreement with Imugene (ASX: IMU), an Australian based biopharmaceutical company, to manufacture and develop its cancer immunotherapy HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SHEIN Expands Compliance Training With UL Solutions

Boosting Seller Compliance Amid Global Standards When you're navigating the cutthroat world of online retail, product compliance isn't just a checkbox—it's your lifeline. SHEIN, a name you're likely familiar with if you're into fast fashion, is doubling down on this by teaming up with UL Solutions. They're holding hands and marching into another training session focused...

Atlantic Blvd Apartments: A Game-Changer for Housing

A Bold Move for Attainable Housing Amidst the hustle and bustle of Sterling, Virginia, a new player has hit the scene: Atlantic Blvd Apartments. A property designed solely for attainable housing, this development is a showcase of what can be accomplished when local government and private developers team up with a shared vision. It feels like a breath of fresh air in a...

TransCode Pursues Strategic Moves for TTX-MC138 Value

A New Chapter for TransCode? Every once in a while, you find companies taking bold steps that make the market look twice. Today, that’s TransCode Therapeutics (NASDAQ: RNAZ) putting their chips on the table, determined to find the best route forward for their oncology efforts. Now, I’ve seen outfits talk plans without substance, but getting Tungsten Advisors on board...

Mission Wealth's Rising Stars Shine Bright in 2026

The financial world can be a ruthless arena, especially when you're under 40 and trying to make your mark. But in 2026, two up-and-comers from Mission Wealth are doing just that—earning spots on the coveted InvestmentNews Rising Stars list. Spotlight on Kulha and Dragan Andrew Kulha, with his legal and financial acumen, breaks down estate strategies like a seasoned...

North Island Credit Union Eases Student Access to Banking

Breaking Down Barriers with Student Banking Services Stumble into any financial setup these days, and you'll hear the same refrain: young people need more access to banking. North Island Credit Union seems to have taken that idea to heart, landing a national Bank On certification for their Student Checking account. It ain't just any badge; it's the mark of reliability,...

Valmet's Strategic Moves and Financial Gains Explained

Valmet's Strategic Playbook for Growth Anyone keeping tabs on Valmet's recent parade of press releases knows they're on a darn aggressive growth spurt. Talk about shaking things up with a firm grip on the paper and forest products sector and beyond. Their interim review from January to September 2026 spells it out with strong orders received and a solid increase in...

Extra Mile Day: 18 Years of Honoring Unsung Heroes

Pedaling for Purpose: A Journey That Sparked a Movement What started as a lone journey across America's roads has turned into a celebrated movement to honor those who often go unnoticed. Back in 2009, Shawn Anderson embarked on an unusual journey. Armed only with a bicycle and determination, he pedaled from San Francisco to Boston—over 4,000 miles in just 90 days. It...

Astellas and Audax Forge $1.34B Immuno-Oncology Deal

Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...

OppFi's Q3 2026: Is Their Growth Strategy on Track?

OppFi's Third Quarter Performance Unpacked OppFi's recent third-quarter disclosures should get investors pondering. They've launched a new line of credit product, plugging a gap in their service portfolio, and aimed to widen their customer net. Their targeted share repurchase of $6.7 million in stock isn't small potatoes either, showing a vote of confidence in their own...

Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...